What is BioXcel Therapeutics?
BioXcel Therapeutics, Inc. is a biopharmaceutical firm leveraging artificial intelligence to pioneer transformative medicines, particularly in the fields of neuroscience and immuno-oncology. Through its wholly owned subsidiary, OnkosXcel Therapeutics, the company is dedicated to developing novel therapeutic agents. The substantial enterprise-level backing indicates a strong market confidence in BioXcel's AI-driven approach to drug discovery and its potential to address unmet medical needs.
How much funding has BioXcel Therapeutics raised?
BioXcel Therapeutics has raised a total of $260M across 1 funding round:
Other Financing Round
$260M
Other Financing Round (2022): $260M with participation from Oaktree Capital Management and Qatar Investment Authority
Key Investors in BioXcel Therapeutics
Oaktree Capital Management
Oaktree Capital Management is a leading global investment management firm specializing in alternative investments, known for its opportunistic and value-oriented approach across credit, equity, and real estate markets. They partner with clients worldwide to identify investment opportunities that balance potential returns with disciplined risk management.
Qatar Investment Authority
Founded in 2005, Qatar Investment Authority is headquartered in Doha, Qatar, specializing in foreign and domestic investment with a focus on listed securities, property, alternative assets, and private equity.
What's next for BioXcel Therapeutics?
The significant capital infusion, characterized as major enterprise-level funding, positions BioXcel Therapeutics for accelerated growth and the advancement of its clinical-stage assets. This strategic investment will likely fuel further research and development, expand its operational capabilities, and support the progression of its drug candidates through rigorous clinical trials. The company's focus on AI-driven drug development suggests a forward-looking strategy aimed at optimizing therapeutic outcomes and market penetration in competitive biopharmaceutical sectors.
See full BioXcel Therapeutics company page
